Sangamo Therapeutics Inc (SGMO)

Apr 22, 2025

Form 4Statement of changes in beneficial ownership of securities - ADVFN

Apr 22, 2025

Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025

Apr 13, 2025

Sangamo announces capsid license agreement with Eli Lilly - MSN

Apr 13, 2025

Apr 07, 2025

Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma

Apr 07, 2025

Apr 04, 2025

Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech

Apr 04, 2025

Apr 04, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025

Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025

Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025

Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025

Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025

Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025

Apr 02, 2025

Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 02, 2025

Apr 02, 2025

5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io

Apr 02, 2025

Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025

Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025

Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025

Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025

Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025

Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025

Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo

Mar 18, 2025

Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 18, 2025

Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com

Mar 18, 2025

Mar 18, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 17, 2025

Sangamo: Q4 Earnings Snapshot - mySA

Mar 17, 2025

Mar 17, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com

Mar 17, 2025

Mar 17, 2025

Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia

Mar 17, 2025

Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India

Mar 17, 2025